Cisplatin: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
Apalmer (talk | contribs)
nocaptcha
14,582 edits
No edit summary
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Protected "Cisplatin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))
(No difference)

Revision as of 19:31, 27 September 2011

Cisplatin
Clinical data
Pregnancy
category
  • US: D (Evidence of risk)
Routes of
administration		Intravenous
ATC code
Pharmacokinetic data
Bioavailabilitycomplete
Protein binding> 90%
Elimination half-life30-100 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaCl2H6N2Pt
Molar mass300.05 g/mol

WikiDoc Resources for Cisplatin

Articles

Most recent articles on Cisplatin

Most cited articles on Cisplatin

Review articles on Cisplatin

Articles on Cisplatin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cisplatin

Images of Cisplatin

Photos of Cisplatin

Podcasts & MP3s on Cisplatin

Videos on Cisplatin

Evidence Based Medicine

Cochrane Collaboration on Cisplatin

Bandolier on Cisplatin

TRIP on Cisplatin

Clinical Trials

Ongoing Trials on Cisplatin at Clinical Trials.gov

Trial results on Cisplatin

Clinical Trials on Cisplatin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cisplatin

NICE Guidance on Cisplatin

NHS PRODIGY Guidance

FDA on Cisplatin

CDC on Cisplatin

Books

Books on Cisplatin

News

Cisplatin in the news

Be alerted to news on Cisplatin

News trends on Cisplatin

Commentary

Blogs on Cisplatin

Definitions

Definitions of Cisplatin

Patient Resources / Community

Patient resources on Cisplatin

Discussion groups on Cisplatin

Patient Handouts on Cisplatin

Directions to Hospitals Treating Cisplatin

Risk calculators and risk factors for Cisplatin

Healthcare Provider Resources

Symptoms of Cisplatin

Causes & Risk Factors for Cisplatin

Diagnostic studies for Cisplatin

Treatment of Cisplatin

Continuing Medical Education (CME)

CME Programs on Cisplatin

International

Cisplatin en Espanol

Cisplatin en Francais

Business

Cisplatin in the Marketplace

Patents on Cisplatin

Experimental / Informatics

List of terms related to Cisplatin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Pharmacology

Upon administration, a chloride ligand undergo slow displacement with water (an aqua ligand) molecules, in a process termed aquation. The aqua ligand in the resulting [PtCl(H2O)(NH3)2]+ is easily displaced, allowing cisplatin to coordinate a basic site in DNA. Subsequently, the platinum cross-links two bases via displacement of the other chloride ligand.[1] Cisplatin crosslinks DNA in several different ways, interfering with cell division by mitosis. The damaged DNA elicits DNA repair mechanisms, which in turn activate apoptosis when repair proves impossible.

Most notable among the DNA changes are the 1,2-intrastrand cross-links with purine bases. These include 1,2-intrastrand d(GpG) adducts which form nearly 90% of the adducts and the less common 1,2-intrastrand d(ApG) adducts. 1,3-intrastrand d(GpXpG) adducts occur but are readily excised by the nucleotide excision repair (NER) . Other adducts include inter-strand crosslinks and nonfunctional adducts that have been postulated to contribute to cisplatin's activity. Interaction with cellular proteins, particularly HMG domain proteins, has also been advanced as a mechanism of interfering with mitosis, although this is probably not its primary method of action.

trans-PtCl2(NH3)2

The trans-[PtCl2(H2O)(NH3)2 does not exhibit a comparably useful pharmacological effect. Its low activity is generally thought to be due to rapid deactivation of the drug before it can arrive at the DNA. It is toxic, and it is desirable to test batches of cis-platin for the absence of the trans isomer. In a procedure by Woollins et al., which is based on the classic 'Kurnakov test', thiourea reacts with the sample to give derivatives are easily separated and detected by HPLC.[2]

Side effects

Cisplatin has a number of side-effects that can limit its use:

  • Nephrotoxicity (kidney damage) is a major concern when cisplatin is given. The dose is reduced when the patient's creatinine clearance (a measure of renal function) is reduced. Adequate hydration and diuresis is used to prevent renal damage. The nephrotoxicity of platinum-class drugs seems to be related to reactive oxygen species and in animal models can be ameliorated by free radical scavenging agents. This is a dose-limiting toxicity.
  • Neurotoxicity (nerve damage) can be anticipated by performing nerve conduction studies before and after treatment.
  • Nausea and vomiting. Cisplatin is one of the most emetogenic chemotherapy agents, but this is managed with prophylactic antiemetics (e.g. ondansetron, granisetron, etc.) in combination with corticosteroids. Aprepitant combined with ondansetron and dexamethasone has been shown to be better for highly emetogenic chemotherapy than just ondansetron and dexamethasone.
  • Ototoxicity (hearing loss): unfortunately there is at present no effective treatment to prevent this side effect, which may be severe. Audiometric analysis may be necessary to assess the severity of ototoxicity. Other drugs (such as the aminoglycoside antibiotic class) may also cause ototoxicity, and the administration of this class of antibiotics in patients receiving cisplatin is generally avoided. The ototoxicity of both the aminoglycosides and cisplatin may be related to their ability to bind to melanin in the stria vascularis of the inner ear or the generation of reactive oxygen species.
  • Alopecia (hair loss): this is generally not a major problem in patients treated with cisplatin.
  • Electrolyte disturbance: Cisplatin can cause hypomagnesaemia, hypokalaemia and hypocalcaemia. The hypocalcaemia seems to occur in those with low serum magnesium secondary to cisplatin, so it is not primarily due to the Cisplatin.

History

The compound cis-PtCl2(NH3)2 was first described by M. Peyrone in 1845 (known as Peyrone's salt).[3] The structure was deduced by Alfred Werner in 1893.[1] In the 1960s, Barnett Rosenberg and van Camp et al at Michigan State University discovered that electrolysis of a platinum electrode produced cisplatin, which inhibited binary fission in Escherichia coli (E. coli) bacteria. The bacteria grow to 300 times their normal length but cell division fails. Rosenberg then conducted a series of experiments to test the effects various platinum coordination complexes on sarcomas artificially implanted in rats. This study found that cis-diamminedichloroplatinum(II) was the most effective out of this group, which started the medicinal career of cisplatin.[4]

Approved for clinical use by the United States Food and Drug Administration (FDA) in 1978, it revolutionized the treatment of certain cancers. Detailed studies on its molecular mechanism of action, using a variety of spectrocopic methods including X-ray, NMR spectroscopy, and other physico-chemical methods, revealed its ability to form irreversible crosslinks with bases in DNA.

Synthesis

Synthesis of cisplatin
Synthesis of cisplatin

The synthesis of cisplatin is a classic in inorganic chemistry. Starting from potassium tetrachloroplatinate, K2PtCl42−, the first NH3 ligand is added to any of the four equivalent positions, but the second NH3 could be added cis or trans to the amine ligand. Because Cl− has a larger trans effect than NH3, the second amine substitutes trans to a chloride ligand, and therefore cis to the first amine. The trans effect of the halides follows the order I->Br->Cl-, therefore the synthesis is conducted using PtI42− to ensure high yield and purity of the cis isomer, followed by conversion of the PtI2(NH3)2 into PtCl2(NH3)2, as first described by Dhara.[5][6]



References

  1. ↑ 1.0 1.1 Stephen Trzaska (20 Jun 05). "Cisplatin". C&EN News. 83 (25). Check date values in: |date= (help)
  2. ↑ J. D. Woollins, A. Woollins and B. Rosenberg (1983). "The detection of trace amounts of trans-Pt(NH3)2Cl2 in the presence of cis-Pt(NH3)2Cl2. A high performance liquid chromatographic application of kurnakow's test". Polyhedron. 2 (3): 175–178. doi:10.1016/S0277-5387(00)83954-6.
  3. ↑ Peyrone M. Ann Chemie Pharm 1845;51:129.
  4. ↑ Rosenberg, B. (1965). "Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode". Nature. 205 (4972): 698–699. doi:10.1038/205698a0. Unknown parameter |coauthors= ignored (help)
  5. ↑ Dhara, S. C. Indian Journal of Chemistry 1970, volume 8, pp. 193–134.
  6. ↑ Rebecca A. Alderden, Matthew D. Hall, and Trevor W. Hambley (2006). "The Discovery and Development of Cisplatin". J. Chem. Ed. 83: 728–724.

External links

Template:SIB

de:Cisplatin nl:Cisplatine Template:WH Template:WS


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Cisplatin&oldid=605962"